Ampliphi Biosciences Corp (APHB) Coverage Initiated at HC Wainwright
Equities research analysts at HC Wainwright assumed coverage on shares of Ampliphi Biosciences Corp (NASDAQ:APHB) in a research note issued on Monday. The firm set a “buy” rating and a $5.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 461.99% from the stock’s current price.
Shares of Ampliphi Biosciences Corp (NASDAQ:APHB) opened at 0.8897 on Monday. Ampliphi Biosciences Corp has a 12 month low of $0.67 and a 12 month high of $18.40. The company has a 50 day moving average of $0.89 and a 200 day moving average of $1.05. The stock’s market cap is $7.78 million.
Ampliphi Biosciences Corp (NASDAQ:APHB) last posted its quarterly earnings results on Monday, August 14th. The company reported ($0.78) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.02. The firm had revenue of $0.03 million for the quarter. Ampliphi Biosciences Corp had a negative return on equity of 159.06% and a negative net margin of 11,193.10%. Equities research analysts expect that Ampliphi Biosciences Corp will post ($10.60) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://www.watchlistnews.com/ampliphi-biosciences-corp-aphb-coverage-initiated-at-hc-wainwright/1530524.html.
Ampliphi Biosciences Corp Company Profile
AmpliPhi Biosciences Corporation is a biotechnology company. The Company is focused on the discovery, development and commercialization of phage therapeutics. The Company is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products.
Receive News & Ratings for Ampliphi Biosciences Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampliphi Biosciences Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.